Literature DB >> 2006276

Graves ophthalmopathy: role of MR imaging in radiation therapy.

M Just1, G Kahaly, H P Higer, H P Rösler, J Kutzner, J Beyer, M Thelen.   

Abstract

Twenty-three patients with Graves ophthalmopathy who underwent radiation therapy were monitored by means of magnetic resonance (MR) imaging. T2 relaxation times of extraocular muscles and orbital fat, areas of extraocular muscles, and degree of exophthalmos were measured by means of MR imaging at the beginning, at the end, and 3 months after completion of radiation therapy. As a result, patients with primarily elevated T2 times of extraocular muscles showed a better therapy response regarding muscle thickening than patients with primarily normal T2 times. Elevated T2 times, which probably represent acute inflammatory changes, were markedly decreased at the end of therapy. Therefore, quantitative MR imaging favors the choice of anti-inflammatory therapy regimens in patients with elevated T2 times of extraocular muscles. However, the clinical response (activity scores) to the low-dose treatment protocol that was used did not correlate well with primarily elevated T2 times. Furthermore, T2 times increased again after cessation of therapy. Whether a higher radiation dose or a different fractionation scheme leads to better results must be clarified by means of further study.

Entities:  

Mesh:

Year:  1991        PMID: 2006276     DOI: 10.1148/radiology.179.1.2006276

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  8 in total

Review 1.  [Inflammatory diseases of the orbit].

Authors:  A Zimmer; W Reith
Journal:  Radiologe       Date:  2008-12       Impact factor: 0.635

2.  Update on advanced imaging options for thyroid-associated orbitopathy.

Authors:  Michael P Rabinowitz; Jacqueline R Carrasco
Journal:  Saudi J Ophthalmol       Date:  2012-10

3.  Orbital Fat Volumetry and Water Fraction Measurements Using T2-Weighted FSE-IDEAL Imaging in Patients with Thyroid-Associated Orbitopathy.

Authors:  Y Kaichi; K Tanitame; H Itakura; H Ohno; M Yoneda; Y Takahashi; Y Akiyama; K Awai
Journal:  AJNR Am J Neuroradiol       Date:  2016-06-30       Impact factor: 3.825

4.  Efficacy of (99m)Tc-EDDA/HYNIC-TOC SPECT/CT scintigraphy in Graves' ophthalmopathy.

Authors:  Rong Zhao; Jiang Wang; Jinglan Deng; Weidong Yang; Jing Wang
Journal:  Am J Nucl Med Mol Imaging       Date:  2012-03-28

5.  Plasma glycosaminoglycans in endocrine ophthalmopathy.

Authors:  G Kahaly; C Hansen; J Beyer; R Winand
Journal:  J Endocrinol Invest       Date:  1994-01       Impact factor: 4.256

Review 6.  Recent developments in Graves' ophthalmopathy imaging.

Authors:  G J Kahaly
Journal:  J Endocrinol Invest       Date:  2004-03       Impact factor: 4.256

7.  Baseline Volumetric T2 Relaxation Time Histogram Analysis: Can It Be Used to Predict the Response to Intravenous Methylprednisolone Therapy in Patients With Thyroid-Associated Ophthalmopathy?

Authors:  Ping Liu; Ban Luo; Lang Chen; Qiu-Xia Wang; Gang Yuan; Gui-Hua Jiang; Jing Zhang
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-25       Impact factor: 5.555

8.  Current insights of applying MRI in Graves' ophthalmopathy.

Authors:  Cheng Song; Yaosheng Luo; Genfeng Yu; Haixiong Chen; Jie Shen
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-29       Impact factor: 6.055

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.